Katy Bradford: Cassette approach offers compelling construction solution
ORNL, a bastion of nuclear physics research for the past 80 years, is poised to strengthen its programs and service to the United States over the next decade if national recommendations of the Nuclear Science Advisory Committee, or NSAC, are enacted.
Speakers, scientific workshops, speed networking, a student poster showcase and more energized the Annual User Meeting of the Department of Energy’s Center for Nanophase Materials Sciences, or CNMS, Aug. 7-10, near Market Square in downtown Knoxville, Tennessee.
Neutron experiments can take days to complete, requiring researchers to work long shifts to monitor progress and make necessary adjustments. But thanks to advances in artificial intelligence and machine learning, experiments can now be done remotely and in half the time.
Creating energy the way the sun and stars do — through nuclear fusion — is one of the grand challenges facing science and technology. What’s easy for the sun and its billions of relatives turns out to be particularly difficult on Earth.
ORNL will team up with six of eight companies that are advancing designs and research and development for fusion power plants with the mission to achieve a pilot-scale demonstration of fusion within a decade.
Oak Ridge National Laboratory researchers serendipitously discovered when they automated the beam of an electron microscope to precisely drill holes in the atomically thin lattice of graphene, the drilled holes closed up.
Larry Allard, a distinguished research staff member at Oak Ridge National Laboratory, has been named a Fellow of the Microanalysis Society.
Oak Ridge National Laboratory researchers are developing a first-of-its-kind artificial intelligence device for neutron scattering called Hyperspectral Computed Tomography, or HyperCT.
A study led by researchers at ORNL could help make materials design as customizable as point-and-click.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.